Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | DRAGON: SRK-181 alone/in combination with anti-PD-L1 treatment in patients with advanced solid tumor

Meredith McKean, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the DRAGON trial, the first-in-human Phase I trial (NCT04291079) of the latent TGFβ1 inhibitor SRK-181 alone or in combination with anti-PD-L1 treatment in patients with advanced solid tumors. The treatment was well-tolerated, with manageable adverse events. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.